Russian Covid-19 Vaccine To Be Cheaper Than Pfizer And Moderna, Says Sputnik V

Sputnik V vaccine which is named after the Soviet Union spacecraft was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.

(Representative Image/ Getty)

Sputnik V, the Russian vaccine candidate for the coronavirus disease on Sunday, confirmed through its official Twitter handle that the Russian developed vaccine’s price will be much lower than the vaccines of the US-based firms such as Pfizer and Moderna.

"Translating pharma lingo: the announced price of Pfizer of USD 19.50 and Moderna of USD 25-USD 37 per dose actually means their price of USD 39 and USD 50-USD 74 per person. Two doses are required per person for the Pfizer, Sputnik V, and Moderna vaccines. The price of Sputnik V will be much lower," the official account said.

In August earlier this year, Russia became the first country to register the world's first COVID-19 vaccine. Sputnik V vaccine which is named after the Soviet Union spacecraft was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.

Later on, November 11, the Russian government said that its vaccine Sputnik V is 92 per cent effective at protecting people from COVID-19 according to the first interim analysis.

After which, the US pharmaceutical giant Moderna, in its official statement, confirmed that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.

Similarly, on November 18, Pfizer in its final results from the late-stage trial of its coronavirus vaccine was found to be 95 per cent effective and had no serious side effects on older people.

As the clinical trials are moving forward, promising results are being confirmed by different vaccine candidates from across the globe in order to counter the Covid-19 disease.

Meanwhile, Bharat Biotech’s “Covaxin” on Sunday, confirmed that the vaccine is 60 per cent effective as results came from the late-stage clinical trials.